Arca Biopharma, Inc. ABIO
We take great care to ensure that the data presented and summarized in this overview for ARCA biopharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ABIO
Top Purchases
Top Sells
About ABIO
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Insider Transactions at ABIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 19
2024
|
Fairmount Funds Management LLC Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
160,000
+16.69%
|
-
|
|
Sep 11
2024
|
Fairmount Funds Management LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
275,000
+30.1%
|
$6,325,000
$23.0 P/Share
|
|
Aug 16
2024
|
Janus Henderson Group PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
5,818
+0.14%
|
$11,636
$2.96 P/Share
|
|
Jul 25
2024
|
Janus Henderson Group PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
30,227
+1.41%
|
$90,681
$3.05 P/Share
|
|
Jul 24
2024
|
Janus Henderson Group PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
189,856
+2.87%
|
$569,568
$3.18 P/Share
|
|
Jul 11
2024
|
Janus Henderson Group PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
94,537
+4.76%
|
$283,611
$3.45 P/Share
|
|
Jul 10
2024
|
Janus Henderson Group PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
55,463
+1.53%
|
$166,389
$3.46 P/Share
|
|
Jul 09
2024
|
Janus Henderson Group PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
16,917
+0.96%
|
$50,751
$3.43 P/Share
|
|
Jul 08
2024
|
Janus Henderson Group PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
47,492
+1.37%
|
$142,476
$3.48 P/Share
|
|
Jul 05
2024
|
Janus Henderson Group PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
28,326
+0.84%
|
$84,978
$3.42 P/Share
|
|
Jul 03
2024
|
Janus Henderson Group PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
166,042
+9.15%
|
$498,126
$3.55 P/Share
|
|
Dec 16
2022
|
Funicular Funds, LP > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
1,420,000
+26.2%
|
$2,840,000
$2.5 P/Share
|
|
Dec 08
2022
|
Thomas A Keuer Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+49.55%
|
-
|
|
Dec 08
2022
|
C. Jeffrey Dekker Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+50.0%
|
-
|
|
Jul 01
2022
|
Funicular Funds, LP > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
2,580,452
+50.0%
|
-
|
|
Jul 01
2022
|
Funicular Funds, LP > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
2,580,452
-50.0%
|
-
|
|
May 25
2022
|
Funicular Fund, LP |
BUY
Open market or private purchase
|
Direct |
64,851
+2.45%
|
$129,702
$2.32 P/Share
|
|
May 24
2022
|
Funicular Fund, LP |
BUY
Open market or private purchase
|
Direct |
18,110
+0.71%
|
$36,220
$2.29 P/Share
|
|
May 23
2022
|
Funicular Fund, LP |
BUY
Open market or private purchase
|
Direct |
2,301
+0.09%
|
$4,602
$2.29 P/Share
|
|
May 19
2022
|
Funicular Fund, LP |
BUY
Open market or private purchase
|
Direct |
1
|
$2
$2.25 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 635K shares |
|---|---|
| Grant, award, or other acquisition | 275K shares |
| Exercise of conversion of derivative security | 160K shares |